Viatris price to free cash flow VTRS
Market value divided by free cash flow over the last twelve months, since 2021.
- Today, Nov 2, 2026
- 11.0×
- 5-year median
- 5.8×
- Against its 5-year history
- 97th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 3.4× to 11.4×
- Peer median
- 21.8×
Viatris' price to free cash flow is 11.0× as of Nov 2, 2026.
That is above its 5-year median of 5.8×, higher than on 97% of days in the last 5 years.
Over that time it ranged from 3.4× in Sep 2022 to 11.4× in Jul 2026.
The median for 10 healthcare stocks of a similar size is 21.8×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 11.0× | 7.8× | 11.4× |
| 2025 | 8.5× | 4.6× | 8.5× |
| 2024 | 7.6× | 5.5× | 8.2× |
| 2023 | 6.2× | 4.4× | 6.4× |
| 2022 | 4.7× | 3.4× | 5.5× |
| 2021 | 4.9× | 4.4× | 5.1× |
Against its peers
Companies in Healthcare nearest Viatris' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| VTRSViatris | 11.0× |
| THCTenet Healthcare | 7.1× |
| ALNYAlnylam Pharmaceuticals | 26.7× |
| STESTERIS | 24.5× |
| INCYIncyte | 12.7× |
| ZBHZimmer Biomet | 12.2× |
| MEDPMedpace | 25.6× |
| UTHRUnited Therapeutics | 23.7× |
| EXELExelixis | 14.8× |
| RVTYRevvity | 30.3× |
| DGXQuest Diagnostics | 20.0× |
| Peer median | 21.8× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Viatris
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.